Firm Receives Government Approval for Psychedelic Therapy Treatment

By: Dylan Sikes – AllPennyStocks.com News

Monday, May 16, 2022

The use of psychedelic treatments for mental health is gaining in popularity. This company just received Canadian approval to provide psychedelic assisted therapy for treatment resistant depression.

On the frontier of mental health advancement, Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) is advancing innovative treatments using safe, evidence-based psychedelic-assisted therapies. The firm received approval from Health Canada to complete psychedelic-assisted therapy using psilocybin to treat an applicant with treatment-resistant depression.

This will be the firm’s first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada's Special Access Program ("SAP”). SAP was amended in early 2022 to include access to psychedelic compounds on a case-by-case basis.

U.S. shares closed Friday at $0.28, up over 15 percent on the day.

Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.